"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Schwarz Pharma Inc.","UCB","$22,000,000","$0","$22,000,000","2010","20100429","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","Schwarz Pharma Inc. agreed to pay $22 million to resolve False Claims Act allegations that the company failed to advise the Centers for Medicare and Medicaid Services that two unapproved products did not qualify for coverage under federal health care programs. Schwarz was alleged to have submitted false quarterly reports to the government related to a pair of drugs, Deponit and Hyoscyamine Sulfate Extended Release.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/schwarz-pharma-pays-22-million-settle-false-claims-allegations-concerning-reimbursement",""
"UCB Inc.","UCB","$34,000,000","$0","$34,000,000","2011","20110609","healthcare-related offenses","off-label or unapproved promotion of medical products","","The U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA. pleaded guilty to the off-label promotion of its epilepsy drug Keppra and will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/us-subsidiary-belgian-pharmaceutical-manufacturer-pleads-guilty-label-promotion-company-pay",""
"SCHWARZ PHARMA MANUFACTURING, INC.","UCB","$6,750","$0","$6,750","2010","20100308","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Indiana","SEYMOUR","1101 C AVENUE WEST","47274","325412","325412: Pharmaceutical Preparation Manufacturing","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"Schwarz Pharma Inc.","UCB","$9,756,164","$9,756,164","$0","2010","20100429","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","Schwarz Pharma agreed to pay more than $9 million to settle multistate litigation alleging that it misrepresented the status of drugs that had been deemed ineligible for reimbursement by government healthcare programs such as Medicaid. This was part of a larger $22 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-schwarz-pharma-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/schwarz-pharma-pays-22-million-settle-false-claims-allegations-concerning-reimbursement",""
"UCB","UCB","$3,350,000","$0","$3,350,000","2013","20131118","government-contracting-related offenses","False Claims Act and related","","The Louisiana Attorney General's Office announced that it had obtained a total of $88 million in settlements from 25 pharmaceutical companies to resolve allegations they overcharged the state's Medicaid program.","state","agency action","Louisiana Attorney General","civil","","","","","","Louisiana","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131206104321/http://www.ag.state.la.us/Article.aspx?articleID=788&catID=2",""
"UCB Holdings, Inc.","UCB","$5,500,000","$0","$5,500,000","2017","20170519","employment-related offenses","benefit plan administrator violation","pension ERISA violation","","federal","private litigation","","civil","","Northern District of Georgia","1:15-cv-0348","Ahrens et al v. UCB Holdings, Inc. et al","settlement","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","",""
"UCB Inc.","UCB","$9,893,322","$9,893,322","$0","2011","20110609","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","UCB Inc. agreed to pay $9.9 million to settle multistate litigation alleging that it promoted the epilepsy drug Keppra for uses not approved by the Food and Drug Administration and thus caused false claims to be submitted to state Medicaid programs. This was part of a larger $34 million civil and criminal settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-ucb-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/us-subsidiary-belgian-pharmaceutical-manufacturer-pleads-guilty-label-promotion-company-pay",""
"UCB Pharma, Inc.","UCB","$2,275,454","$0","$2,275,454","2009","20091202","competition-related offenses","price-fixing or anti-competitive practices","","A group of 11 companies agreed to pay a total of $25.03 million to settle multistate litigation alleging they conspired to fix the prices of vitamins added to foods such as ready-to-eat cereals. The announcement did not specify how much each company would pay. Here we assume the total was divided equally among them.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Belgium","","publicly traded","","pharmaceuticals","pharmaceuticals","http://www.illinoisattorneygeneral.gov/pressroom/2009_12/20091202.html",""
